It’s only fair to share… VIXOTRIGINE, NEW PATENT, WO-2019071162, BIOGEN INC https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2019071162&redirectedID=true vixotrigine Process for preparing α-carboxamide pyrrolidine derivatives (particularly vixotrigine ) and its intermediates are modulators of use-dependent voltage-gated sodium channels Biogen, following the acquisition of Convergence Pharmaceuticals, that previously acquired clinical assets from GSK is developing vixotrigine a voltage-gated sodium channel 1.7 inhibitor, for the …
Tag «VIXOTRIGINE»
VIXOTRIGINE, раксатригин , راكساتريجين , 维索曲静 ,
It’s only fair to share… VIXOTRIGINE Molecular FormulaC18H19FN2O2 Average mass314.354 Da раксатригин , راكساتريجين , 维索曲静 , (5R)-5-{4-[(2-Fluorobenzyl)oxy]phényl}-L-prolinamide 10287 2-Pyrrolidinecarboxamide, 5-[4-[(2-fluorophenyl)methoxy]phenyl]-, (2S,5R)- 934240-30-9 [RN] QQS4J85K6Y Raxatrigine UNII:QQS4J85K6Y Vixotrigine (INN, USAN), formerly known as raxatrigine (INN, USAN), is an analgesic which is under development by Convergence Pharmaceuticals for the treatment of lumbosacral radiculopathy (sciatica) and trigeminal neuralgia (TGN).[1][2][3] Vixotrigine was originally claimed to be a selective central Nav1.3 blocker, but was subsequently redefined as a selective peripheral Nav1.7 blocker.[4]Following this, vixotrigine …